<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120935</url>
  </required_header>
  <id_info>
    <org_study_id>IFOM-CPO003/2018/PO002</org_study_id>
    <nct_id>NCT04120935</nct_id>
  </id_info>
  <brief_title>ALFAOMEGA Master Observational Trial</brief_title>
  <acronym>ALFAOMEGA</acronym>
  <official_title>A Master Protocol Empowering Precision Research in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IFOM, The FIRC Institute of Molecular Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IFOM, The FIRC Institute of Molecular Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between&#xD;
      tumor and host cells in a cohort of CRC patients, with the aim of understanding how their&#xD;
      outcomes can be significantly improved (e.g. reduction of their chance of recurrence and&#xD;
      survival improval). This clinical resource for integrative clinical data and sample&#xD;
      collection will allow the molecular story-telling of CRC metastatic spread along time and&#xD;
      space and the selection of appropriate patients for experimentally-driven trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AlfaOmega is an observational study that will follow a stage-mixed cohort of at least 500&#xD;
      patients through their course of treatments, until death or a minimum of 5 years. Patients&#xD;
      will be longitudinally sampled and matched clinical data (including imaging) will be&#xD;
      collected. Via a multi-tiered informed consensus process, AlphaOmega will also allow to&#xD;
      develop companion diagnostics for molecular enrichment strategies in AIRC-driven&#xD;
      proof-of-concept trials. To achieve the required level of 'experimental precision', patients&#xD;
      will enter AlphaOmega at two different 'therapeutic checkpoints': i) prior to a surgical&#xD;
      event or ii) prior to a systemic treatment. In the latter case patients with no previous&#xD;
      lines of therapy for metastatic disease will be privileged.&#xD;
&#xD;
      To optimize the enrollment of patients, the longitudinal collection of data/samples and their&#xD;
      logistic management, AlphaOmega has been designed as a flexible infrastructure organized in&#xD;
      TIERS for the stepwise comprehension of the biological processes that drive tumor evolution,&#xD;
      and precisely:&#xD;
&#xD;
        -  TIER1, Monitoring: the ability to follow CRC evolution under standard of care treatments&#xD;
           and to define new evolution-linked biomarkers. This will be achieved through the&#xD;
           collection of clinical data, imaging data, FFPE tissue and frozen plasma/PBMC.&#xD;
&#xD;
        -  TIER2, Modelling: the ability to develop pertinent experimental models to study&#xD;
           evolutionary mechanisms and define evolution-targeting therapeutic strategies. This will&#xD;
           be achieved through the collection of Fresh Tissue, Whole Blood, Stools, Buccal Swabs&#xD;
           and other fluids.&#xD;
&#xD;
        -  TIER3, Linking: the ability to access data and samples of patients enrolled in&#xD;
           proof-of-concept trials to prove the efficacy and study/understand resistance mechanisms&#xD;
           of evolution-targeting therapies. This will be achieved by introducing the connection in&#xD;
           the trial protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients longitudinally monitored</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of recruited CRC cases in TIER1 with complete FFPE/clinical data match.&#xD;
- Number of recruited CRC cases in TIER2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients triaged in proof-of-concept (POC) clinical trials</measure>
    <time_frame>6 months</time_frame>
    <description>Number of CRC cases recruited in TIER3.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of new prognostic and predictive biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of identified/validated new prognostic markers&#xD;
- Number of identified/validated new predictive markers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of new prognostic and predictive biomarkers with clinical outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>- Correlation between identified biomarkers with therapies response rates (RR).&#xD;
- Correlation between identified biomarkers with progression-free survival (PFS).&#xD;
- Correlation between identified biomarkers with overall survival (OS).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
    <description>Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Prospective Observation of standard clinical practice.</description>
    <arm_group_label>Cohort of CRC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  FFPE Tissue&#xD;
&#xD;
        -  Fresh Tissue (tumor and normal)&#xD;
&#xD;
        -  Plasma&#xD;
&#xD;
        -  PBMC&#xD;
&#xD;
        -  Whole Blood&#xD;
&#xD;
        -  Stools&#xD;
&#xD;
        -  Buccal Swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. TIER1 written Informed consent.&#xD;
&#xD;
          2. Patients ≥18 years of age.&#xD;
&#xD;
          3. Previous diagnosis of colorectal cancer, or a strong suspicion of CRC based on&#xD;
             clinical and radiological findings.&#xD;
&#xD;
          4. In patients with previous diagnosis of CRC availability of diagnostic Formalin-Fixed,&#xD;
             Paraffin Embedded (FFPE) blocks (surgical resection and/or tumor biopsies), or at&#xD;
             least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.&#xD;
&#xD;
          5. ECOG Performance status &lt; 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5&#xD;
             years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ&#xD;
             cervical cancer)&#xD;
&#xD;
          2. Patient unable to comply with the study protocol owing to psychological, social or&#xD;
             geographical reasons.&#xD;
&#xD;
          3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus&#xD;
             (HCV) or syphilis infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Silvia Marsoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFOM, The FIRC Institute of Molecular Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Luraghi, PhD</last_name>
    <phone>+3902574303799</phone>
    <email>paolo.luraghi@ifom.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luca Lazzari, PhD</last_name>
    <phone>+3902574303799</phone>
    <email>luca.lazzari@ifom.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Pietrantonio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milan</city>
        <state>Mi</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giulia Zampino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niguarda Cancer Center - ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Siena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto (IOV)</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Lonardi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - IRCCS</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Fenocchio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Degiuli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Sciallero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AUSL della Romagna - Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar - Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Montagut, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Tabernero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moises Broggi</name>
      <address>
        <city>Barcelona</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Vivas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INCLIVA - Instituto de Investigatión Sanitaria</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Cervantes, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

